2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2476 Evolution of clinical practice in steroid-refractory graft-versus-host disease – a five-year comparison of two EBMT surveys by the complications working party (CWP)

Zinaida Peric, Christophe Peczynski2, William Boreland3, Mouad Abouqateb4, Hélène M Schoemans, MD, PhD5, Ivan Moiseev6, Charlotte E. Graham7, Alberto Mussetti8, Lars Gjaerde9, Mahmoud Aljurf10, Daniel Wolff, MD11, Steven Z. Pavletic, MD, PhD12, Olaf Penack13
1 Complications Working Party, EBMT, Paris, France, Faculty of Medicine, Rijeka, Croatia, University Hospital Centre Rijeka, Rijeka, Croatia
2 Complications Working Party, EBMT, Paris, France
3 Complications Working Party, EBMT, Paris, France
4 Complications Working Party, EBMT, Paris, France
5 Complications Working Party, EBMT, Paris, France, University Hospitals Leuven, Leuven, Belgium
6 Complications Working Party, EBMT, Paris, France, RM Gorbacheva Research Institute, Pavlov University, St Petersburg, Russian Federation
7 Complications Working Party, EBMT, Paris, France, King's College London, London, United Kingdom
8 Complications Working Party, EBMT, Paris, France, Institut Català d'Oncología, Barcelona, Spain
9 Complications Working Party, EBMT, Paris, France, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
10 King Faisal Hospital, Riyadh, Saudi Arabia
11 University Hospital of Regensburg, Regensburg, Germany
12 Faculty of Medicine, Rijeka, Croatia
13 Complications Working Party, EBMT, Paris, France, University Hospital Charité Berlin, Berlin, Germany

Introduction: Steroid-refractory acute and chronic GVHD (SR-aGVHD and SR-cGVHD) remain major causes of morbidity and mortality after allogeneic transplantation. Prospective evidence, regulatory approvals and access to new agents, particularly ruxolitinib and belumosudil, have changed the treatment landscape. Whether these developments have standardized clinical practice and altered treatment sequencing is unknown.

Methods: CWP performed a 40-question survey on management of SR-aGVHD and SR-cGVHD among EBMT centers in 2021 and 2026. The objective of this study was to compare the results of the two surveys conducted five years apart and describe changes in the GVHD practice focusing on corticosteroid (CS) dosing, response assessment, standard operating procedures (SOPs), and treatments used after CS failure.

Results: Between 2021 and 2026 participation increased from 145 centers in 33 countries to 174 centers in 39 countries. Initial CS practice for aGVHD remained unchanged in aGVHD grades >2b with most centers (2021:88% vs 2026:87%) starting with higher doses of CS (2mg/kg) while it became more standardized in lower grade aGVHD (grade 2a) with more centers (68% vs 79%) starting with lower doses (< 2mg/kg). Timing of response remained heterogeneous and response evaluation was done at 3 days in 33% vs 39% centers, at 5 days in 30% vs 26% centers, at 7 days at 15% vs 16% centers and depending on severity of aGVHD in most other centers. The proportion of centers reporting to have SOPs for SR-aGVHD stayed the same (85%). Ruxolitinib became the most used treatment after steroid failure in aGVHD, increasing from the use in 72% to 96% centers. Use in this setting declined for previously most used agents; extracorporeal photopheresis (ECP): 63% to 43%, calcineurin inhibitors (CNI): 33% to 16%, mycophenolate mofetil (MMF): 30% to 10%, mesenchymal stem cells (MSC): 18% to 12%, high-dose CS: 15% to 7%, etanercept: 15% to 6% and infliximab: 15% to 5% centers. Finally, most used third-line agents in 2026 included ECP in 60%, MSC in 36%, ruxolitinib in 26%, vedolizumab in 25%, fecal microbiota transplantation (FMT) in 24%, MMF and etanercept in 15%, CNI in 13% and infliximab in 12% centers, while α1-Antitrypsin was used in <10% centers.

Initial treatment of mild cGVHD stayed similar with only topical treatment used in 58% (2021) vs 55% (2026) centers. Initial management of moderate/severe cGVHD became more standardized around CS 0.5–1 mg/kg, increasing from 71% to 78% centers, while addition of CNI declined from 52% to 36%. Response assessment was done in 41% vs 49% of centers before 4 weeks, 41% vs 39% between 5-8 weeks, while minority of centers performed later evaluation. SR-cGVHD SOPs availability increased from 65% to 77%. Ruxolitinib also consolidated its position as most used salvage treatment for SR-cGVHD, increasing from the use in 71% to 89% centers, while belumosudil was used in 27% centers in 2026. Use of most other therapies in second-line declined: ECP 74% to 55% of centers, CNI 55% to 25%, MMF 41% to 18%, rituximab 30% to 14%, imatinib 29% to 9%, ibrutinib 29% to 9%, mTOR inhibitors 23% to 12%, methotrexate (MTX) 20% to 10%, pulse of CS 18% to 4% and MSC 12% to 9%. Belumosudil emerged as dominant third-line option used in 61% centers, followed by ECP (55%), rituximab (28%), ruxolitinib (27%), ibrutinib and MMF (21%), MSC and mTOR inhibitors (18%), imatinib (14%), and MTX (11%), while axatilimab was used in <10% centers.

Conclusions: While first-line CS practice in the management of GVHD became more standardized over the last five years, timing of CS-response assessment remained variable, suggesting that definitions of steroid refractoriness are not yet fully standardized. Ruxolitinib became the dominant initial salvage treatment for both SR-aGVHD and SR-cGVHD, while ECP and conventional therapies appear to have shifted toward later treatment lines. Use of vedolizumab and FMT indicates growing interest in gut and microbiome-directed approaches in third-line SR-aGVHD while belumosudil was rapidly incorporated, particularly in third-line SR-cGVHD treatment. Overall, newer agents have established a more recognizable treatment sequence, but they have not eliminated uncertainty regarding optimal sequencing, organ-specific selection, access or later-line management. Future priorities include prospective comparative studies, harmonized definitions and response-assessment schedules, as well as evidence-based treatment algorithms.

Zinaida Peric: Sanofi - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)